Users online: 3501    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 3
First page : ( 1346) Last page : ( 1350)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00248.6

Development and validated of spectrophotometric methods for the determination of Selexipag (An anti-hypertensive agent)

Prathyusha Sistla Mounica*, Deepti Choppala Asha, Naik Raghu Raj

Mukthinuthalapati Mathrusri Annapurna GITAM Institute of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam-530045, India

*Corresponding Author E-mail: pratyushasistla07@gmail.com

Online published on 22 April, 2020.


Selexipag is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Selexipag is a selective prostacyclin receptor agonist. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects. New zero order and first derivative spectrophotometric methods have been proposed for the determination of Selexipag in pharmaceutical formulations. Selexipag obeys Beer-Lambert's law over the concentration range 10–60 μg/ml for all the above mentioned methods and all the methods are validated as per ICH guidelines.



Selexipag, Spectroscopy, Phosphate buffer, Borate buffer, Validation.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
496,647,646 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.